

## LETTER TO THE EDITOR

# A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19

To the Editor,

No therapeutics has been proven effective for treatment of coronavirus disease 2019 (COVID-19).<sup>1,2</sup> China has explored important clinical trials on a host of possible effective treatment options including ozone therapy. We introduced our experience in treating two confirmed cases by ozone therapy—major autohemotherapy (MAH).<sup>3</sup> After the written informed consent was obtained, MAH was given to patients once daily for 7 consecutive days. Each time, 100 mL of venous blood was collected and mixed with O<sub>3</sub> gas at the 1:1 ratio of oxygen-ozone to blood volume, with the final concentration of oxygen-ozone being 20 µg/mL. The clinical study was approved by the Clinical Research Ethics Committee of Renmin Hospital of Wuhan University (WDRY2020-K020).

## CASE 1

A male of 53-year-old was admitted to Renmin Hospital of Wuhan University on 20 February 2020 due to mild fever and dyspnea for 7 days, accompanied by headache, runny nose, fatigue, and loss of appetite. On admission, he presented a clear consciousness with a body temperature of 37.5°C. Chest computed tomography (CT) imaging on 19 February 2020 revealed multiple small patchy shadows, linear interstitial changes, and consolidation in both lungs. He was confirmed COVID-19 on 21 February 2020. Lymphopenia, elevated C-reactive protein and interleukin 6, mild hypoxemia were noted in laboratory tests.

After admission, the patient was given antiviral therapy, antibiotics, immunoglobulin, omeprazole, supplemental oxygen of

**TABLE 1** Demographics, clinical and laboratory results of cases with or without ozone therapy

Parameters (normal range)	Ozone therapy				Without ozone therapy			
	Case 1		Case 2		Case 1		Case 2	
	Baseline	after treatment	Baseline	after treatment	Baseline	after treatment	Baseline	after treatment
Age y, sex	53, M		66, M		65, M		48, M	
WBC (3.5-9.5×10 <sup>9</sup> /L)	4.27	7.73	9.06	7.62	2.37	8.88	7.16	6.58
N (1.8-6.3×10 <sup>9</sup> /L)	2.68	5.70	6.32	4.7	1.49	6.61	4.12	4.2
L (1.1-3.2×10 <sup>9</sup> /L)	0.73	1.40	1.77	2.15	0.59	1.6	2.12	1.76
Platelet count (125-350×10 <sup>9</sup> /L)	271	201	220	156	196	251	142	211
CRP (0-10 mg/L)	51.8	<5.0	108.4	<5.0	181.2	<5.0	77.3	8.0
Alkaline phosphatase (45-125 U/L)	52	59	53	57	43	54	70	89
Bilirubin (0-23 mmol/L)	4.8	7.3	13.9	4.43	5.7	11.7	10.1	7.1
Creatinine (57-111 µmol/L)	48	55	47	48	98	66	106	89
Creatine kinase (18-198 U/L)	466	22	48	17	225	31	56	46
LDH (120-250 U/L)	283	140	263	211	302	210	336	198
Oximetry saturation (≥95%)	94	99	99	...	93	...	100	97
PaO <sub>2</sub> (80-100 mm Hg)	68	163	159	...	65	...	173	92
PaCO <sub>2</sub> (35-45 mm Hg)	45	48	37	...	38	...	39	42
Ultra-TnI (0-0.04 ng/mL)	<0.006	<0.006	0.077	<0.006	<0.006	0.012	<0.006	<0.006
IL-6 (≤20.0 pg/mL)	28.26	4.58	...	...	...	...	2.09	6.68
IL-10 (≤5.9 pg/mL)	7.47	6.70	...	...	...	...	4.68	5.38
Duration of viral shedding, d	14		13		26		43	
Length in hospital, d	23		17		28		41	

Abbreviations: CRP, C-reactive protein; IL, interleukin; LDH, lactate dehydrogenase; WBC, white blood cell.

3 L/min. He was treated with O<sub>3</sub>-MAH on 25 February 2020 once daily for 7 consecutive days. With the treatment of MAH, his symptoms disappeared soon. Abnormal laboratory indicators within normal range were recorded (Table 1). Compared to baseline chest imaging, follow-up serial CT scans showed gradually absorbed bilateral lung lesions (Figure S1). The patient was discharged on 14 March 2020 after nuclei acid tests negative twice consecutively on nasopharyngeal swabs and meeting other discharge criteria.<sup>4</sup> No MAH-related adverse events were reported.

## CASE 2

A male of 66-year-old was referred from a community clinic on 5 February 2020. He suffered from fever on 22 January 2020 accompanied by cough and sore throat, with the highest body temperature of 39.2°C. He had a history of chronic respiratory disease. For chest CT scan on 23 January 2020 showed "viral pneumonia-like changes," the patient was admitted to a community health center with "suspected COVID-19" and confirmed COVID-19 on 25 January 2020. However, antiviral therapy and antibiotics did not improve his condition, cough, hemoptysis, and dyspnea occurred. Repeated chest CT scan revealed lesion progression, with multiple ground-glass opacities and interstitial changes in both lungs.

After referred, he was given antiviral therapy, antibiotics, immunoglobulin, supplemental oxygen of 3 L/min. The patient was treated with O<sub>3</sub>-MAH since 15 February 2020, once daily for 7 consecutive days. After MAH treatment, he recovered rapidly with normal range of laboratory indicators. Compared to baseline chest imaging, follow-up CT scan showed obviously absorbed bilateral lung lesions (Figure S1). After meeting the discharge criteria,<sup>4</sup> the patient left hospital on 22 February 2020. No MAH-related adverse events occurred.

To show the advantages of this treatment, the two cases were compared with other two subjects without MAH, being age- and illness severity-matched. We found that the patients without MAH had longer duration of viral shedding and length of hospital stay.

## DISCUSSION

We present the possibility of ozone therapy as a treatment for COVID-19 in two severe confirmed cases. MAH was carried out to each patient for 7 days. After treatment, two patients remitted symptoms and discharged with negative reverse transcription polymerase chain reaction testing for severe acute respiratory syndrome coronavirus 2.

No specific therapeutic agents have been confirmed to be effective to COVID-19, therefore, a number of antiviral drugs or therapeutic measures have been tested in China. Ozone therapy has been continuously used for a decades-long history of practices, especially in Europe for a variety of infectious, immunological, and circulatory conditions.<sup>3</sup> Recently, the potential effect of ozone on viral inactivation in vivo has been found.<sup>3</sup> Studies have also reported

the efficacy and safety of ozone administration on patients of human immunodeficiency virus (HIV), hepatitis C, Ebola, influenza.<sup>3,5,6</sup> As a new immunotherapy and an inexpensive, safe modality, ozone therapy has its rationality in the treatment of COVID-19 patients,<sup>7,8</sup> which was confirmed by our preliminary observational results. However, its use combined with other treatments may be justified and synergic.<sup>7</sup> Since the treatments for four patients with COVID-19 were followed the recommendation outlined in *the Chinese Guidelines*,<sup>4</sup> we think ozone therapy may be responsible for the good effects observed in the two cases.

In short, ozone therapy may be a useful modality in controlling COVID-19 infection, however, further clinical studies are needed to determine effectiveness, optimal ozone dosage, and appropriate treatment duration.

## ACKNOWLEDGMENTS

The authors wish to express gratitude to Beijing Sincoheren S&T Development Co, Ltd for generously donating one ozone generators for use for COVID-19 in East Campus, Renmin Hospital of Wuhan University. None of the authors have any financial disclosures to make. This study was supported by the Science and Technology Key Project on Novel Coronavirus Pneumonia, Hubei Province, China (project number: 2020FCA002).

## CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

Zhishui Zheng MD

Minglin Dong MD

Ke Hu MD 

*Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China*

## Correspondence

Ke Hu, MD, Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Zhangzhidong Road No 99, Wuhan 430060, China.  
Email: [huke-rmhospital@163.com](mailto:huke-rmhospital@163.com)

## Funding Information

Science and Technology Key Project on Novel Coronavirus Pneumonia, Hubei Province, China, Grant/Award Number: 2020FCA002

## ORCID

Ke Hu  <http://orcid.org/0000-0001-9862-7239>

## REFERENCES

1. Wu JT, Leung K, Leung GM. Now casting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet*. 2020; 395(10225):689-697.

2. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. *N Engl J Med*. 2020;382(19):1787-1799. <https://doi.org/10.1056/NEJMoa2001282>
3. Smith NL, Wilson AL, Gandhi J, Vatsia S, Khan SA. Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility. *Med Gas Res*. 2017;7(3):212-219.
4. National Health Commission of the People's Republic of China. Diagnosis and treatment of novel coronavirus infected pneumonia (trial 7th edition) [EB/OL]. [2020-03-03]. <http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf>
5. Rowen RJ, Robins H, Carew K, et al. Rapid resolution of hemorrhagic fever (Ebola) in Sierra Leone with ozone therapy. *Afr J Infect Dis*. 2016; 10(1):49-54.
6. Zaky S, Kamel SE, Hassan MS, et al. Preliminary results of ozone therapy as a possible treatment for patients with chronic hepatitis C. *J Altern Complement Med*. 2011;17(3):259-263.
7. Ricevuti G, Franzini M, Valdenassi L. Oxygen-ozone immunocellular therapy in COVID-19 outbreak: facts and figures. *Ozone Therapy*. 2020;5:9014.
8. Rowen RJ, Robins HR. A plausible "penny" costing effective treatment for corona virus-ozone therapy. *J Infect Dis Epidemiol*. 2020;6(2):113.

#### SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.